{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:42:55Z","timestamp":1791416575945,"version":"4.3.3"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Science and Technology Fund Project of Guizhou Provincial Health Commission of China","award":["gzwjkj2020-1\u2013034"],"award-info":[{"award-number":["gzwjkj2020-1\u2013034"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p\/>\n               <jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>The aim of this study was to investigate the effect of preoperative radiotherapy (PrORT) on the overall survival (OS) of patients with stage ipsilateral mediastinal lymph node metastasis (N2) non-small-cell lung cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>A total of 1390 patients with stage N2 non-small-cell lung cancer between 2010 and 2015 were identified from the Surveillance, Epidemiology, and End Results database. The efficacy of PrORT combined with surgery was compared with that of surgery alone on OS. Propensity score matching (PSM) was performed to balance the baseline characteristics of patients who received (n\u2009=\u2009239) and did not receive (n\u2009=\u20091151) PrORT. We compared the OS of the 2 groups using the Kaplan\u2013Meier method and log-rank were used to compare the OS between the 2 groups test before and after PSM and to analyse subgroups of patients with squamous cell carcinoma (SCC) and adenocarcinoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>In whole group analysis before PSM, the median OS was superior in the PrORT group than in the surgery alone group (44.0 [34.4\u201356.6] vs 39.0 [34.5\u201343.5] months). There was a significant difference in OS [hazard ratio (HR): 0.819; 95% confidence interval (CI): 0.677\u20130.991; P\u2009=\u20090.029]. Nevertheless, no statistically significant difference was found in OS between the 2 groups after PSM (HR: 0.856; 95% CI: 0.654\u20131.122; P\u2009=\u20090.260). Among subgroup analysis of the SCC group before PSM revealed that patients who received PrORT had significantly higher median OS than those who did not receive PrORT (52.0 [40.0\u2013NA] vs 27.0 [22.0\u201332.0] months; HR: 0.591, 95% CI: 0.442\u20130.792, P\u2009=\u20090.000) and the differences in OS existed after PSM (P\u2009=\u20090.043). However, no significant difference was found in OS before and after matching in the adenocarcinoma group (P\u2009=\u20090.827 and P\u2009=\u20090.801, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>PrORT demonstrated an OS benefit for patients with stage N2 lung SCC; however, further prospective randomized clinical trials are warranted to confirm this finding.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/icvts\/ivab321","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T19:10:29Z","timestamp":1634843429000},"source":"Crossref","is-referenced-by-count":4,"title":["Effect of preoperative radiotherapy on overall survival in N2 non-small-cell lung cancer: a propensity score-matched analysis of Surveillance, Epidemiology, and End Results database"],"prefix":"10.1093","volume":"35","author":[{"given":"Yunan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, The Second Affiliated Hospital of Zun Yi Medical University , Zunyi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunliang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, The Second Affiliated Hospital of Zun Yi Medical University , Zunyi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjia","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, The Second Affiliated Hospital of Zun Yi Medical University , Zunyi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyi","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, The Second Affiliated Hospital of Zun Yi Medical University , Zunyi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"He","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, The Second Affiliated Hospital of Zun Yi Medical University , Zunyi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, The Second Affiliated Hospital of Zun Yi Medical University , Zunyi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, The Second Affiliated Hospital of Zun Yi Medical University , Zunyi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"2022070412470545500_ivab321-B1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2022070412470545500_ivab321-B2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(10)60059-1","article-title":"Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data","volume":"375","author":"NSCLC Meta-analyses Collaborative Group","year":"2010","journal-title":"Lancet"},{"key":"2022070412470545500_ivab321-B3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/14737140.2014.867809","article-title":"Controversies in the management of stage III non-small-cell lung cancer","volume":"14","author":"Biswas","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"2022070412470545500_ivab321-B4","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1002\/cncr.26689","article-title":"A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903)","volume":"118","author":"Katakami","year":"2012","journal-title":"Cancer"},{"key":"2022070412470545500_ivab321-B5","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1200\/JCO.1995.13.8.1880","article-title":"Concurrent cisplatin\/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and TIIB non-small-cell lung cancer: mature results of southwest oncology group phase II study 8805","volume":"13","author":"Albain","year":"1995","journal-title":"J Clin Oncol"},{"key":"2022070412470545500_ivab321-B6","author":"National Comprehensive Cancer Network (NCCN)","year":"2021"},{"key":"2022070412470545500_ivab321-B7","doi-asserted-by":"crossref","first-page":"E466","DOI":"10.1016\/j.ijrobp.2017.06.1717","article-title":"Optimal timing of postoperative radiotherapy for patients with Piiia-N2 non-small cell lung cancer after resection","volume":"99","author":"Kang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022070412470545500_ivab321-B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.2280","article-title":"LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683","volume":"31","author":"Le Pechoux","year":"2020","journal-title":"Ann Oncol"},{"key":"2022070412470545500_ivab321-B9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1186\/s12885-018-4900-x","article-title":"Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung cancer undergoing surgery: a propensity-matched analysis","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"key":"2022070412470545500_ivab321-B10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cac2.12153","article-title":"Neoadjuvant immunotherapy for non-small cell lung cancer: state of the art","volume":"41","author":"Kang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"2022070412470545500_ivab321-B11","first-page":"61","article-title":"Research progress of neoadjuvant therapy in stage IIIA-N2 non-small cell lung cancer","volume":"29","author":"Sun","year":"2020","journal-title":"Chin J Radiat Oncol"},{"key":"2022070412470545500_ivab321-B12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/bjc.1998.560","article-title":"Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study","volume":"78","author":"Shepherd","year":"1998","journal-title":"Br J Cancer"},{"key":"2022070412470545500_ivab321-B13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/jnci\/86.9.673","article-title":"A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IDA non-small-cell lung cancer","volume":"86","author":"Roth","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"2022070412470545500_ivab321-B14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0169-5002(99)00045-8","article-title":"Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial","volume":"26","author":"Rosell","year":"1999","journal-title":"Lung Cancer"},{"key":"2022070412470545500_ivab321-B15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijrobp.2011.11.069","article-title":"Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung","volume":"84","author":"Suntharalingam","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022070412470545500_ivab321-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2017.3092","article-title":"Quality of lymph node assessment and survival among patients with non-small cell lung cancer","volume":"4","author":"Choe","year":"2018","journal-title":"JAMA Oncol"},{"key":"2022070412470545500_ivab321-B17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2009.10.003","article-title":"Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial","volume":"69","author":"Girard","year":"2010","journal-title":"Lung Cancer"},{"key":"2022070412470545500_ivab321-B18","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"2022070412470545500_ivab321-B19","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1186\/s12885-020-07309-y","article-title":"The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study","volume":"20","author":"Duan","year":"2020","journal-title":"BMC Cancer"},{"key":"2022070412470545500_ivab321-B20","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.21037\/jtd.2017.10.47","article-title":"Optimal managements of stage IIIA (N2) non-small cell lung cancer patients: a population-based survival analysis","volume":"9","author":"Pang","year":"2017","journal-title":"J Thorac Dis"},{"key":"2022070412470545500_ivab321-B21","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1002\/cam4.1701","article-title":"Preoperative radiation may improve the outcomes of resectable IIIA\/N2 non-small-cell lung cancer patients: a propensity score matching-based analysis from surveillance, epidemiology, and end results database","volume":"7","author":"Chen","year":"2018","journal-title":"Cancer Med"},{"key":"2022070412470545500_ivab321-B22","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"2022070412470545500_ivab321-B23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"2022070412470545500_ivab321-B24","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"2022070412470545500_ivab321-B25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022070412470545500_ivab321-B26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/jso.24677","article-title":"Prognostic value of visceral pleural invasion in non-small cell lung cancer: a propensity score matching study based on the SEER registry","volume":"116","author":"Yang","year":"2017","journal-title":"J Surg Oncol"},{"key":"2022070412470545500_ivab321-B27","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.athoracsur.2018.04.071","article-title":"Lobectomy versus sublobectomy in metachronous second primary lung cancer: a propensity score study","volume":"106","author":"Yang","year":"2018","journal-title":"Ann Thorac Surg"}],"container-title":["Interactive CardioVascular and Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/icvts\/advance-article-pdf\/doi\/10.1093\/icvts\/ivab321\/43882843\/ivab321.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/icvts\/article-pdf\/35\/1\/ivab321\/44394886\/ivab321.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/icvts\/article-pdf\/35\/1\/ivab321\/44394886\/ivab321.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T12:47:37Z","timestamp":1656938857000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/icvts\/article\/doi\/10.1093\/icvts\/ivab321\/6594118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/icvts\/ivab321","relation":{},"ISSN":["1569-9293","1569-9285"],"issn-type":[{"value":"1569-9293","type":"print"},{"value":"1569-9285","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,5,27]]},"article-number":"ivab321"}}